首页 > 最新文献

Cardiology journal最新文献

英文 中文
Diagnostic value of soluble urokinase-type plasminogen activator receptor in patients with acute coronary syndrome: A systematic review and meta-analysis. 可溶性尿激酶型纤溶酶原激活物受体对急性冠状动脉综合征患者的诊断价值:系统综述和荟萃分析。
Pub Date : 2024-01-01 Epub Date: 2023-09-29 DOI: 10.5603/cj.96228
Michal Pruc, Iwona Jannasz, Damian Swieczkowski, Grzegorz Procyk, Aleksandra Gasecka, Zubaid Rafique, Francesco Chirico, Nicola Luigi Bragazzi, Milosz J Jaguszewski, Jaroslaw Wysocki, Lukasz Szarpak

Background: In contemporary clinical practice, there is an increasing need for new clinically relevant biomarkers potentially optimizing management strategies in patients with suspected acute coronary syndrome (ACS). This study aimed to determine the diagnostic utility of soluble urokinase-type plasminogen activator receptor (suPAR) levels in individuals with suspected ACS.

Methods: A literature search was performed in Web of Science, PubMed, Scopus, and the Cochrane Central Register of Controlled Trials databases, for studies comparing suPAR levels among patients with and without ACS groups. The methodological quality of the included papers was assessed using the Newcastle-Ottawa Scale (NOS). A fixed-effects model was used if I² < 50%; otherwise, the random-effects model was performed.

Results: Five studies with 3417 participants were included in the meta-analysis. Pooled analysis showed that mean suPAR levels in the ACS group were statistically significantly higher than in the control group (3.56 ± 1.38 vs. 2.78 ± 0.54 ng/mL, respectively; mean difference: 1.04; 95% confidence interval: 0.64-1.44; I² = 99%; p < 0.001).

Conclusions: In the context of acute coronary syndrome, suPAR is a potential biomarker for the early identification of medical conditions in individuals who are being treated in emergency rooms.

背景:在当代临床实践中,越来越需要新的临床相关生物标志物,这可能会优化疑似急性冠状动脉综合征(ACS)患者的管理策略。本研究旨在确定可溶性尿激酶型纤溶酶原激活物受体(suPAR)水平对疑似ACS患者的诊断作用。方法:在Web of Science、PubMed、Scopus和Cochrane Central Register of Controlled Trials数据库中进行文献检索,以比较ACS组和非ACS组患者的suPAR水平。采用纽卡斯尔-渥太华量表(NOS)评估纳入论文的方法学质量。如果I²<50%,则使用固定效应模型;否则,执行随机效应模型。结果:荟萃分析包括5项研究,共3417名参与者。综合分析显示,ACS组的平均suPAR水平在统计学上显著高于对照组(分别为3.56±1.38 vs.2.78±0.54 ng/mL;平均差异:1.04;95%置信区间:0.64-1.44;I²=99%;p<0.001),suPAR是一种潜在的生物标志物,用于早期识别在急诊室接受治疗的个人的医疗状况。
{"title":"Diagnostic value of soluble urokinase-type plasminogen activator receptor in patients with acute coronary syndrome: A systematic review and meta-analysis.","authors":"Michal Pruc, Iwona Jannasz, Damian Swieczkowski, Grzegorz Procyk, Aleksandra Gasecka, Zubaid Rafique, Francesco Chirico, Nicola Luigi Bragazzi, Milosz J Jaguszewski, Jaroslaw Wysocki, Lukasz Szarpak","doi":"10.5603/cj.96228","DOIUrl":"10.5603/cj.96228","url":null,"abstract":"<p><strong>Background: </strong>In contemporary clinical practice, there is an increasing need for new clinically relevant biomarkers potentially optimizing management strategies in patients with suspected acute coronary syndrome (ACS). This study aimed to determine the diagnostic utility of soluble urokinase-type plasminogen activator receptor (suPAR) levels in individuals with suspected ACS.</p><p><strong>Methods: </strong>A literature search was performed in Web of Science, PubMed, Scopus, and the Cochrane Central Register of Controlled Trials databases, for studies comparing suPAR levels among patients with and without ACS groups. The methodological quality of the included papers was assessed using the Newcastle-Ottawa Scale (NOS). A fixed-effects model was used if I² < 50%; otherwise, the random-effects model was performed.</p><p><strong>Results: </strong>Five studies with 3417 participants were included in the meta-analysis. Pooled analysis showed that mean suPAR levels in the ACS group were statistically significantly higher than in the control group (3.56 ± 1.38 vs. 2.78 ± 0.54 ng/mL, respectively; mean difference: 1.04; 95% confidence interval: 0.64-1.44; I² = 99%; p < 0.001).</p><p><strong>Conclusions: </strong>In the context of acute coronary syndrome, suPAR is a potential biomarker for the early identification of medical conditions in individuals who are being treated in emergency rooms.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11374330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41157403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Are we at dawn of the drug-coated balloons era? Current evidence, future directions, and tasks of the newly established working group of the Association of Cardiovascular Interventions. 药物涂层球囊时代来临了吗?当前证据、未来方向以及心血管介入协会新成立工作组的任务。
Pub Date : 2024-01-01 DOI: 10.5603/cj.98927
Sylwia Iwańczyk, Kamil Bujak, Rafał Wolny, Adam Janas, Miłosz Dziarmaga, Maksymilian P Opolski, Rafał Januszek, Adrian Włodarczak, Piotr Desperak, Piotr Niezgoda, Michał Kryjak, Mariusz Tomaniak, Zenon Huczek, Michał Hawranek, Bernardo Cortese, Wojciech Wańha
{"title":"Are we at dawn of the drug-coated balloons era? Current evidence, future directions, and tasks of the newly established working group of the Association of Cardiovascular Interventions.","authors":"Sylwia Iwańczyk, Kamil Bujak, Rafał Wolny, Adam Janas, Miłosz Dziarmaga, Maksymilian P Opolski, Rafał Januszek, Adrian Włodarczak, Piotr Desperak, Piotr Niezgoda, Michał Kryjak, Mariusz Tomaniak, Zenon Huczek, Michał Hawranek, Bernardo Cortese, Wojciech Wańha","doi":"10.5603/cj.98927","DOIUrl":"10.5603/cj.98927","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11374319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality of life in heart failure: New data, new drugs and devices. 心力衰竭患者的生活质量:新数据、新药物和设备。
Pub Date : 2024-01-01 Epub Date: 2023-10-12 DOI: 10.5603/cj.92243
Katarzyna Major, Aleksandra Bodys-Pełka, Marcin Grabowski, Małgorzata Lelonek

Quality of life (QoL) is a therapeutic goal in heart failure. There are many EBM therapies for improving QoL. In this study, data is presented on new pharmacotherapies and devices that impact QoL in the heart failure population.

生活质量(QoL)是心力衰竭的一个治疗目标。有许多EBM疗法可以改善生活质量。在这项研究中,提供了影响心力衰竭人群生活质量的新药物疗法和设备的数据。
{"title":"Quality of life in heart failure: New data, new drugs and devices.","authors":"Katarzyna Major, Aleksandra Bodys-Pełka, Marcin Grabowski, Małgorzata Lelonek","doi":"10.5603/cj.92243","DOIUrl":"10.5603/cj.92243","url":null,"abstract":"<p><p>Quality of life (QoL) is a therapeutic goal in heart failure. There are many EBM therapies for improving QoL. In this study, data is presented on new pharmacotherapies and devices that impact QoL in the heart failure population.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10919569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41223564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Statins and the risk of pancreatic cancer: A systematic review and meta-analysis of 2,797,186 patients. 他汀类药物与胰腺癌风险:一项对2,797,186例患者的系统回顾和荟萃分析。
Pub Date : 2024-01-01 Epub Date: 2022-04-04 DOI: 10.5603/CJ.a2022.0014
Eryka Karbowska, Damian Swieczkowski, Aleksandra Gasecka, Michal Pruc, Kamil Safiejko, Jerzy R Ladny, Tomasz Kopiec, Milosz J Jaguszewski, Krzysztof J Filipiak, Zubaid Rafique, Lukasz Szarpak

Background: Statin use in many studies is related to the improvement of a patients' condition including reducing the risk of various malignancies. Herein, is a systematic review and meta-analysis to examine the evidence on the association between statin therapy and the risk of the occurrence of pancreatic cancer, mainly in terms of decreased risk of developing pancreatic cancer among patients using statin therapy in the long-term perspective.

Methods: PubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from database inception to December 1st, 2021. Random effect models were used to estimate summary odds ratios (OR) and the corresponding 95% confidence intervals (CI).

Results: A total of 26 studies comprising 2,797,186 patients were included. Polled analysis showed that pancreatic cancer occurrence in statin vs. no-statin group varied and amounted to 0.4% vs. 0.6% (RR = 0.83; 95% CI: 0.72-0.96; I² = 84%; p = 0.01).

Conclusions: In summary, the present analysis shows that overall statins use is significantly associated with a reduction in risk of pancreatic cancer. However, these results were not confirmed for the randomized controlled trial subgroup. Further prospective studies are needed to confirm the current results.

背景:在许多研究中,他汀类药物的使用与患者病情的改善有关,包括降低各种恶性肿瘤的风险。本文通过系统综述和荟萃分析,研究他汀类药物治疗与胰腺癌发生风险之间相关性的证据,主要是从长期角度来看,他汀类药物治疗可降低患者患胰腺癌的风险。方法检索spubmed、Web of Science、Scopus和Cochrane Central Register of Controlled Trials (Central)数据库自建库至2021年12月1日的数据。随机效应模型用于估计总优势比(OR)和相应的95%置信区间(CI)。结果共纳入26项研究,2,797,186例患者。调查分析显示,他汀类药物组和非他汀类药物组的胰腺癌发生率有所不同,分别为0.4%和0.6% (RR = 0.83;95% ci: 0.72-0.96;I²= 84%;P = 0.01)。综上所述,目前的分析表明,他汀类药物的总体使用与胰腺癌风险的降低显著相关。然而,这些结果在随机对照试验亚组中没有得到证实。需要进一步的前瞻性研究来证实目前的结果。
{"title":"Statins and the risk of pancreatic cancer: A systematic review and meta-analysis of 2,797,186 patients.","authors":"Eryka Karbowska, Damian Swieczkowski, Aleksandra Gasecka, Michal Pruc, Kamil Safiejko, Jerzy R Ladny, Tomasz Kopiec, Milosz J Jaguszewski, Krzysztof J Filipiak, Zubaid Rafique, Lukasz Szarpak","doi":"10.5603/CJ.a2022.0014","DOIUrl":"10.5603/CJ.a2022.0014","url":null,"abstract":"<p><strong>Background: </strong>Statin use in many studies is related to the improvement of a patients' condition including reducing the risk of various malignancies. Herein, is a systematic review and meta-analysis to examine the evidence on the association between statin therapy and the risk of the occurrence of pancreatic cancer, mainly in terms of decreased risk of developing pancreatic cancer among patients using statin therapy in the long-term perspective.</p><p><strong>Methods: </strong>PubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from database inception to December 1st, 2021. Random effect models were used to estimate summary odds ratios (OR) and the corresponding 95% confidence intervals (CI).</p><p><strong>Results: </strong>A total of 26 studies comprising 2,797,186 patients were included. Polled analysis showed that pancreatic cancer occurrence in statin vs. no-statin group varied and amounted to 0.4% vs. 0.6% (RR = 0.83; 95% CI: 0.72-0.96; I² = 84%; p = 0.01).</p><p><strong>Conclusions: </strong>In summary, the present analysis shows that overall statins use is significantly associated with a reduction in risk of pancreatic cancer. However, these results were not confirmed for the randomized controlled trial subgroup. Further prospective studies are needed to confirm the current results.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46352304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bivalirudin versus heparin in contemporary percutaneous coronary interventions for patients with acute coronary syndrome: a systematic review and meta-analysis. 比伐鲁定与肝素在当代急性冠脉综合征患者经皮冠状动脉介入治疗中的应用:一项系统综述和荟萃分析。
Pub Date : 2024-01-01 Epub Date: 2023-11-15 DOI: 10.5603/cj.90956
Junyan Zhang, Zhongxiu Chen, Duolao Wang, Chen Li, Fangbo Luo, Yong He

Background: Bivalirudin is associated with fewer major bleeding events than heparin in patients undergoing percutaneous coronary intervention (PCI), but confounding effects of concomitant glycoprotein IIb/IIIa inhibitors, routine femoral artery access, and less potent effects of clopidogrel limits meaningful comparisons. The present study is a systematic review and meta-analysis to compare bivalirudin to heparin in contemporary practice.

Methods: The Cochrane Library, PubMed, EMBASE, and Ovid MEDLINE databases were searched for relevant studies, including comparisons between bivalirudin and heparin in the current medical era from inception to December 23, 2021. Studies reporting incidences of major adverse cardiac events (MACE) and net adverse clinical events (NACE) in patients undergoing PCI and meeting the inclusion criteria were retained. Data extraction was performed by three independent reviewers.

Results: The meta-analysis included 8 studies. Compared to heparin, bivalirudin during PCI was associated with a lower NACE risk, lower all-cause death, and similar MACE risk, with a pooled risk ratio of 0.82 (95% confidence interval [CI] 0.69-0.97, p = 0.02), 0.83 (95% CI 0.74-0.94, p = 0.002), and 0.93 (95% CI 0.78-1.10, p = 0.38), respectively. Moreover, the reduction in NACE was mainly attributed to reduced bleeding (22% reduction in the risk of major bleeding, 95% CI 0.63-0.97, p = 0.03).

Conclusions: These findings suggest that bivalirudin use during PCI reduced the risk of NACE and all-cause death but did not reduce the risk of MACE compared with heparin use in PCI. More studies specifically designed for anticoagulation strategies and a personalized anticoagulation regimen to comprehensively balance bleeding and ischemia risks are required.

背景:在接受经皮冠状动脉介入治疗(PCI)的患者中,比伐鲁定与肝素相比较少发生大出血事件,但同时使用糖蛋白IIb/IIIa抑制剂、常规股动脉通路和氯吡格雷作用较弱的混杂效应限制了有意义的比较。本研究是一项系统综述和荟萃分析,比较比伐鲁定和肝素在当代实践中的应用。方法:检索Cochrane Library、PubMed、EMBASE和Ovid MEDLINE数据库的相关研究,包括比伐鲁定和肝素在当前医学时代从成立到2021年12月23日的比较。报告PCI患者主要不良心脏事件(MACE)和净不良临床事件(NACE)发生率并符合纳入标准的研究被保留。数据提取由三名独立审稿人完成。结果:meta分析纳入8项研究。与肝素相比,比伐鲁定在PCI期间与较低的NACE风险、较低的全因死亡和相似的MACE风险相关,合并风险比分别为0.82(95%可信区间[CI] 0.69-0.97, p = 0.02)、0.83 (95% CI 0.74-0.94, p = 0.002)和0.93 (95% CI 0.78-1.10, p = 0.38)。此外,NACE的降低主要归因于出血的减少(大出血风险降低22%,95% CI 0.63-0.97, p = 0.03)。结论:这些发现表明,与肝素相比,PCI中使用比伐鲁定可降低NACE和全因死亡的风险,但不能降低PCI中使用MACE的风险。需要更多专门设计抗凝策略和个性化抗凝方案的研究,以全面平衡出血和缺血风险。
{"title":"Bivalirudin versus heparin in contemporary percutaneous coronary interventions for patients with acute coronary syndrome: a systematic review and meta-analysis.","authors":"Junyan Zhang, Zhongxiu Chen, Duolao Wang, Chen Li, Fangbo Luo, Yong He","doi":"10.5603/cj.90956","DOIUrl":"10.5603/cj.90956","url":null,"abstract":"<p><strong>Background: </strong>Bivalirudin is associated with fewer major bleeding events than heparin in patients undergoing percutaneous coronary intervention (PCI), but confounding effects of concomitant glycoprotein IIb/IIIa inhibitors, routine femoral artery access, and less potent effects of clopidogrel limits meaningful comparisons. The present study is a systematic review and meta-analysis to compare bivalirudin to heparin in contemporary practice.</p><p><strong>Methods: </strong>The Cochrane Library, PubMed, EMBASE, and Ovid MEDLINE databases were searched for relevant studies, including comparisons between bivalirudin and heparin in the current medical era from inception to December 23, 2021. Studies reporting incidences of major adverse cardiac events (MACE) and net adverse clinical events (NACE) in patients undergoing PCI and meeting the inclusion criteria were retained. Data extraction was performed by three independent reviewers.</p><p><strong>Results: </strong>The meta-analysis included 8 studies. Compared to heparin, bivalirudin during PCI was associated with a lower NACE risk, lower all-cause death, and similar MACE risk, with a pooled risk ratio of 0.82 (95% confidence interval [CI] 0.69-0.97, p = 0.02), 0.83 (95% CI 0.74-0.94, p = 0.002), and 0.93 (95% CI 0.78-1.10, p = 0.38), respectively. Moreover, the reduction in NACE was mainly attributed to reduced bleeding (22% reduction in the risk of major bleeding, 95% CI 0.63-0.97, p = 0.03).</p><p><strong>Conclusions: </strong>These findings suggest that bivalirudin use during PCI reduced the risk of NACE and all-cause death but did not reduce the risk of MACE compared with heparin use in PCI. More studies specifically designed for anticoagulation strategies and a personalized anticoagulation regimen to comprehensively balance bleeding and ischemia risks are required.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076038/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"107593124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current understanding of Duchenne muscular dystrophy - a purported interview with a purported expert. 目前对杜兴氏肌肉萎缩症的认识--对所谓专家的访谈。
Pub Date : 2024-01-01 DOI: 10.5603/cj.94330
Jarosław Meyer-Szary, Szymon Mikulski
{"title":"Current understanding of Duchenne muscular dystrophy - a purported interview with a purported expert.","authors":"Jarosław Meyer-Szary, Szymon Mikulski","doi":"10.5603/cj.94330","DOIUrl":"10.5603/cj.94330","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11229802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141473591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Percutaneous transaxillary approach for balloon aortic valvuloplasty and complex percutaneous coronary intervention with Impella support. 经皮经腋窝方法进行球囊主动脉瓣成形术和有 Impella 支持的复杂经皮冠状动脉介入治疗。
Pub Date : 2024-01-01 Epub Date: 2024-01-22 DOI: 10.5603/cj.96161
Jerzy Sacha, Krzysztof Krawczyk, Przemysław Lipski, Piotr Feusette, Marek Gierlotka
{"title":"Percutaneous transaxillary approach for balloon aortic valvuloplasty and complex percutaneous coronary intervention with Impella support.","authors":"Jerzy Sacha, Krzysztof Krawczyk, Przemysław Lipski, Piotr Feusette, Marek Gierlotka","doi":"10.5603/cj.96161","DOIUrl":"10.5603/cj.96161","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10919560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139514395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Electrophysiology lab efficiency using cryoballoon for pulmonary vein isolation in central and eastern Europe: A sub-analysis of the cryo global registry study. 中欧和东欧使用冷冻球囊进行肺静脉隔离的电生理学实验室效率:冷冻全球注册研究子分析。
Pub Date : 2024-01-01 Epub Date: 2024-08-13 DOI: 10.5603/cj.98292
Csaba Földesi, Dejan Kojić, Adriana Sudzinova, Marcin Kuniewicz, Petr Neužil, Zoltan Csanadi, Martin Škamla, Martin Svetlošák, Janusz Romanek, Reece Holbrook, Martin Stefanic, Alicia Sale, Thomas R Holmes, Paweł Ptaszyński

Background: Cryoballoon ablation for treatment of atrial fibrillation (AF) reduces procedure times, but limited data is available about its impact on electrophysiology (EP) lab efficiency in Central and Eastern Europe (CEE). Using CEE-specific procedure data, the present study modeled cryoballoon ablation procedures on EP lab resource consumption to improve efficiency.

Methods: A discrete event simulation model was developed to assess EP efficiency with cryoballoon ablation. Model inputs were taken from CEE sites within the Cryo Global Registry, namely Czech Republic, Hungary, Poland, Serbia, and Slovakia. The main endpoints were percentage of days that resulted in overtime and percentage of days with time for one extra simple EP procedure. Use of the 'figure of 8' (Fo8) closure technique to reduce procedure time was also examined.

Results: The mean lab occupancy time across all CEE sites was 133 ± 47 minutes (min: 104 minutes, max:181 minutes). Cryoballoon ablation in the base-case scenario resulted in 14.6% of days with overtime and 64.8% of days with time for an extra simple EP procedure. Use of the Fo8 closure technique enhanced these values to 5.5% and 85.3%, respectively. Model endpoints were most sensitive to changes in lab occupancy times and overtime start time.

Conclusions: In this CEE-specific analysis of EP lab efficiency it was found that 3 cryoballoon ablation procedures could be performed in 1 lab day, leaving time for a 4th simple EP procedure on most days. As such, use cryoballoon ablation for PVI is an effective way to improve EP lab efficiency.

背景:低温球囊消融术治疗心房颤动(房颤)可缩短手术时间,但有关其对中欧和东欧(CEE)电生理学(EP)实验室效率影响的数据有限。本研究利用中欧和东欧特定的手术数据,模拟了冷冻气球消融手术对电生理学实验室资源消耗的影响,以提高效率:方法:开发了一个离散事件模拟模型来评估急诊室冷冻气球消融术的效率。模型输入来自冷冻全球注册中心的中欧和东欧地区,即捷克共和国、匈牙利、波兰、塞尔维亚和斯洛伐克。主要终点是导致加班的天数百分比和有时间进行一次额外简单 EP 手术的天数百分比。此外,还考察了使用 "8 字形"(Fo8)闭合技术缩短手术时间的情况:所有 CEE 站点的平均实验室占用时间为 133 ± 47 分钟(最短:104 分钟,最长:181 分钟)。在基本情况下,冷冻气球消融术导致14.6%的超时天数和64.8%的超时天数用于额外的简单急诊手术。使用 Fo8 封闭技术后,这些数值分别增加到 5.5% 和 85.3%。模型终点对实验室占用时间和加班开始时间的变化最为敏感:在这项针对急诊心电图实验室效率的 CEE 分析中发现,在实验室的一天内可以完成 3 个冷冻气球消融手术,在大多数情况下还能留出时间进行第 4 个简单的急诊心电图手术。因此,使用冷冻气球消融术进行 PVI 是提高 EP 实验室效率的有效方法。
{"title":"Electrophysiology lab efficiency using cryoballoon for pulmonary vein isolation in central and eastern Europe: A sub-analysis of the cryo global registry study.","authors":"Csaba Földesi, Dejan Kojić, Adriana Sudzinova, Marcin Kuniewicz, Petr Neužil, Zoltan Csanadi, Martin Škamla, Martin Svetlošák, Janusz Romanek, Reece Holbrook, Martin Stefanic, Alicia Sale, Thomas R Holmes, Paweł Ptaszyński","doi":"10.5603/cj.98292","DOIUrl":"10.5603/cj.98292","url":null,"abstract":"<p><strong>Background: </strong>Cryoballoon ablation for treatment of atrial fibrillation (AF) reduces procedure times, but limited data is available about its impact on electrophysiology (EP) lab efficiency in Central and Eastern Europe (CEE). Using CEE-specific procedure data, the present study modeled cryoballoon ablation procedures on EP lab resource consumption to improve efficiency.</p><p><strong>Methods: </strong>A discrete event simulation model was developed to assess EP efficiency with cryoballoon ablation. Model inputs were taken from CEE sites within the Cryo Global Registry, namely Czech Republic, Hungary, Poland, Serbia, and Slovakia. The main endpoints were percentage of days that resulted in overtime and percentage of days with time for one extra simple EP procedure. Use of the 'figure of 8' (Fo8) closure technique to reduce procedure time was also examined.</p><p><strong>Results: </strong>The mean lab occupancy time across all CEE sites was 133 ± 47 minutes (min: 104 minutes, max:181 minutes). Cryoballoon ablation in the base-case scenario resulted in 14.6% of days with overtime and 64.8% of days with time for an extra simple EP procedure. Use of the Fo8 closure technique enhanced these values to 5.5% and 85.3%, respectively. Model endpoints were most sensitive to changes in lab occupancy times and overtime start time.</p><p><strong>Conclusions: </strong>In this CEE-specific analysis of EP lab efficiency it was found that 3 cryoballoon ablation procedures could be performed in 1 lab day, leaving time for a 4th simple EP procedure on most days. As such, use cryoballoon ablation for PVI is an effective way to improve EP lab efficiency.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544417/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141972462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intravenous iron supplementation improves energy metabolism of exercising skeletal muscles without effect on either oxidative stress or inflammation in male patients with heart failure with reduced ejection fraction. 静脉补铁改善了运动骨骼肌的能量代谢,对射血分数降低的男性心力衰竭患者的氧化应激或炎症没有影响。
Pub Date : 2024-01-01 Epub Date: 2023-10-19 DOI: 10.5603/cj.97253
Marcin D Drozd, Michał Tkaczyszyn, Monika Kasztura, Kinga Węgrzynowska-Teodorczyk, Irena Flinta, Waldemar Banasiak, Piotr Ponikowski, Ewa A Jankowska

Background: Skeletal muscle dysfunction is a feature of heart failure (HF). Iron deficiency (ID) is prevalent in patients with HF associated with exercise intolerance and poor quality of life. Intravenous iron in iron deficient patients with HF has attenuated HF symptoms, however the pathomechanisms remain unclear. The aim of study was to assess whether intravenous iron supplementation as compared to placebo improves energy metabolism of skeletal muscles in patients with HF.

Methods: Men with heart failure with reduced ejection fraction (HFrEF) and ID were randomised in 1:1 ratio to either intravenous ferric carboxymaltose (IV FCM) or placebo. In vivo reduction of lactates by exercising skeletal muscles of forearm was analyzed. A change in lactate production between week 0 and 24 was considered as a primary endpoint of the study.

Results: There were two study arms: the placebo and the IV FCM (12 and 11 male patients with HFrEF). At baseline, there were no differences between these two study arms. IV FCM therapy as compared to placebo reduced the exertional production of lactates in exercising skeletal muscles. These effects were accompanied by a significant increase in both serum ferritin and transferrin saturation in the IV FCM arm which was not demonstrated in the placebo arm.

Conclusions: Intravenous iron supplementation in iron deficient men with HFrEF improves the functioning of skeletal muscles via an improvement in energy metabolism in exercising skeletal muscles, limiting the contribution of anaerobic reactions generating ATP as reflected by a lower in vivo lactate production in exercising muscles in patients with repleted iron stores.

背景:骨骼肌功能障碍是心力衰竭的一个特征。缺铁(ID)在与运动不耐受和生活质量差相关的HF患者中普遍存在。缺铁性心衰患者静脉注射铁可以减轻心衰症状,但其发病机制尚不清楚。本研究的目的是评估静脉补铁与安慰剂相比是否能改善HF患者骨骼肌的能量代谢。方法:将射血分数(HFrEF)和ID降低的心力衰竭男性按1:1的比例随机分配给静脉注射羧麦芽糖铁(IV FCM)或安慰剂。分析了运动前臂骨骼肌对乳酸盐的体内还原作用。第0周至第24周乳酸生成的变化被认为是该研究的主要终点。结果:有两个研究组:安慰剂组和IV FCM组(12名和11名男性HFrEF患者)。在基线时,这两个研究组之间没有差异。与安慰剂相比,IV FCM治疗减少了运动骨骼肌中乳酸盐的分泌。这些影响伴随着IV FCM组血清铁蛋白和转铁蛋白饱和度的显著增加,而安慰剂组没有证明这一点。结论:HFrEF的缺铁男性静脉补铁通过改善运动骨骼肌的能量代谢来改善骨骼肌的功能,限制厌氧反应产生ATP的作用,这反映在铁储备充足的患者运动肌肉中体内乳酸生成较低。
{"title":"Intravenous iron supplementation improves energy metabolism of exercising skeletal muscles without effect on either oxidative stress or inflammation in male patients with heart failure with reduced ejection fraction.","authors":"Marcin D Drozd, Michał Tkaczyszyn, Monika Kasztura, Kinga Węgrzynowska-Teodorczyk, Irena Flinta, Waldemar Banasiak, Piotr Ponikowski, Ewa A Jankowska","doi":"10.5603/cj.97253","DOIUrl":"10.5603/cj.97253","url":null,"abstract":"<p><strong>Background: </strong>Skeletal muscle dysfunction is a feature of heart failure (HF). Iron deficiency (ID) is prevalent in patients with HF associated with exercise intolerance and poor quality of life. Intravenous iron in iron deficient patients with HF has attenuated HF symptoms, however the pathomechanisms remain unclear. The aim of study was to assess whether intravenous iron supplementation as compared to placebo improves energy metabolism of skeletal muscles in patients with HF.</p><p><strong>Methods: </strong>Men with heart failure with reduced ejection fraction (HFrEF) and ID were randomised in 1:1 ratio to either intravenous ferric carboxymaltose (IV FCM) or placebo. In vivo reduction of lactates by exercising skeletal muscles of forearm was analyzed. A change in lactate production between week 0 and 24 was considered as a primary endpoint of the study.</p><p><strong>Results: </strong>There were two study arms: the placebo and the IV FCM (12 and 11 male patients with HFrEF). At baseline, there were no differences between these two study arms. IV FCM therapy as compared to placebo reduced the exertional production of lactates in exercising skeletal muscles. These effects were accompanied by a significant increase in both serum ferritin and transferrin saturation in the IV FCM arm which was not demonstrated in the placebo arm.</p><p><strong>Conclusions: </strong>Intravenous iron supplementation in iron deficient men with HFrEF improves the functioning of skeletal muscles via an improvement in energy metabolism in exercising skeletal muscles, limiting the contribution of anaerobic reactions generating ATP as reflected by a lower in vivo lactate production in exercising muscles in patients with repleted iron stores.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076021/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in myocarditis management in the light of the latest research and recent guidelines of the European Society of Cardiology. 根据最新研究成果和欧洲心脏病学会的最新指导方针,推进心肌炎的治疗。
Pub Date : 2024-01-01 Epub Date: 2024-01-22 DOI: 10.5603/cj.95175
Aleksandra Chabior, Agata Tymińska, Agnieszka Pawlak, Andrea Giordani, Alida Caforio, Marcin Grabowski, Krzysztof Ozierański

Myocarditis remains an unknown disease with varying clinical manifestations, often leading to heart failure. The latest 2021 and 2022 guidelines of the European Society of Cardiology (ESC) are the first official European documents updating knowledge on the diagnosis and treatment of myocarditis since the 2013 ESC expert consensus statement. These guidelines and new studies allow standardization and improvements to the management of myocarditis. In this review, we discuss the most important aspects of myocarditis diagnosis, therapies and follow-up based on current knowledge.

心肌炎仍是一种未知疾病,临床表现各不相同,通常会导致心力衰竭。欧洲心脏病学会(ESC)最新发布的2021年和2022年指南是自2013年ESC专家共识声明以来第一份更新心肌炎诊断和治疗知识的欧洲官方文件。这些指南和新的研究使心肌炎的治疗得到了标准化和改进。在本综述中,我们将根据目前的知识讨论心肌炎诊断、治疗和随访的最重要方面。
{"title":"Advances in myocarditis management in the light of the latest research and recent guidelines of the European Society of Cardiology.","authors":"Aleksandra Chabior, Agata Tymińska, Agnieszka Pawlak, Andrea Giordani, Alida Caforio, Marcin Grabowski, Krzysztof Ozierański","doi":"10.5603/cj.95175","DOIUrl":"10.5603/cj.95175","url":null,"abstract":"<p><p>Myocarditis remains an unknown disease with varying clinical manifestations, often leading to heart failure. The latest 2021 and 2022 guidelines of the European Society of Cardiology (ESC) are the first official European documents updating knowledge on the diagnosis and treatment of myocarditis since the 2013 ESC expert consensus statement. These guidelines and new studies allow standardization and improvements to the management of myocarditis. In this review, we discuss the most important aspects of myocarditis diagnosis, therapies and follow-up based on current knowledge.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139514388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cardiology journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1